Loading clinical trials...

Acute Effect of Exenatide on Brain Glucose Metabolism | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Acute Effect of Exenatide on Brain Glucose Metabolism

Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function

NCT01588418•The University of Texas Health Science Center at San Antonio

Summary

This research study will examine brain glucose metabolism after an overnight fast to determine the effect of exenatide on brain glucose metabolism and lipid metabolism.

Detailed Description

This study will elucidate if exenatide has an effect on brain glucose metabolism. This will be accomplished by measuring the rate of glucose binding in various brain regions by Positron Emission Tomography (PET) after glucose load with exenatide injection and compare it with placebo injection measured in the same subject. The changes will be compared with peripheral and hepatic glucose metabolism and lipolysis.

Eligibility

Age

18 - 65 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•1. Males age 18-65 years old
•2. Patients must have Body Mass Index (BMI) between 25 and 40 kg/m2
•3. 2-hour glucose concentration above 140mg/dl after 75g glucose load, ie, having impaired glucose tolerance or newly diagnosed type 2 diabetes.
•4. Patients must have BMI of 25-40 kg/m2
•5. Patients must have no known severe liver or kidney disease, cancer, neurologic, psychiatric or systemic disease, ability to understand the study.
•6. Only patients whose body weight has been stable (±3-4 pounds) over the three months prior to study will be included.
•7. Patients must have the following laboratory values:
•* Hematocrit ≥ 34 vol%
•* Serum creatinine\* ≤ 1.5 mg/dl in males and
•* Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT): ≤ 2.5 times upper limit of normal
+3 more criteria

Exclusion Criteria

•Patients are excluded from participation in the study if they meet any of the following criteria:
•1. Patients with major chronic illness (cancer, liver, kidney, cardiovascular disease)
•2. Patients with BMI over 40 and under 25
•3. Patient with age below 18 yrs and over 65 yrs
•4. Female subjects
•5. Patients with type 1 diabetes
•6. Patients treated for type 2 diabetes
•7. Subjects with normal glucose tolerance (NGT)

Locations (1)

Texas Diabetes Institute and UTHSCSA

San Antonio, Texas, United States

Key Dates

Start Date

July 1, 2010

Primary Completion Date

July 1, 2015

Completion Date

July 1, 2015

Last Updated

November 24, 2017

Enrollment

ACTUAL participants

Conditions

Impaired Glucose Tolerance (IGT)Diabetes

Interventions

Exenatide

DRUG

Placebo

DRUG

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

View study

RECRUITINGNA

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 24, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Acute Effect of Exenatide on Brain Glucose Metabolism

Inclusion Criteria

Exclusion Criteria

Genetic Studies of Insulin and Diabetes

Feasibility of a Tailored Online Self-compassion Intervention

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes